Laura Chico
Stock Analyst at Wedbush
(3.72)
# 767
Out of 5,090 analysts
229
Total ratings
47.47%
Success rate
8.24%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $31 | $20.30 | +52.71% | 9 | Dec 5, 2025 | |
| PHVS Pharvaris | Maintains: Outperform | $27 → $30 | $27.82 | +7.86% | 8 | Nov 13, 2025 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $35 → $36 | $42.66 | -15.61% | 2 | Nov 7, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $35 → $32 | $23.87 | +34.06% | 11 | Nov 7, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $44 → $46 | $44.90 | +2.46% | 10 | Nov 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $73 → $77 | $191.83 | -59.86% | 8 | Nov 6, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $22 → $32 | $30.96 | +3.36% | 8 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Neutral | $28 → $13 | $13.10 | -0.76% | 10 | Oct 15, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $15 → $11 | $3.68 | +199.32% | 3 | Sep 30, 2025 | |
| PEPG PepGen | Maintains: Outperform | $9 → $8 | $5.33 | +50.09% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $12.52 | +43.83% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $5.93 | +136.29% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $44.69 | -3.78% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $35.39 | -9.58% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.38 | +48.15% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $5.87 | +138.50% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $153.75 | -8.29% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $36.60 | -7.10% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.86 | +129.15% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $126.75 | +2.56% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $181.82 | -33.45% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $13.38 | -70.10% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $42.61 | -38.98% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.64 | +83.49% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $22.05 | +31.55% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.34 | +61.29% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $32.49 | +29.29% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.67 | +1,542.77% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $9.77 | -48.82% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $53.82 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $5.06 | -1.19% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.61 | +1,445.27% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $10.70 | +6,628.97% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $220.51 | +26.98% | 1 | Apr 21, 2017 |
Denali Therapeutics
Dec 5, 2025
Maintains: Outperform
Price Target: $30 → $31
Current: $20.30
Upside: +52.71%
Pharvaris
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $27.82
Upside: +7.86%
Maze Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $42.66
Upside: -15.61%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $23.87
Upside: +34.06%
Dianthus Therapeutics
Nov 6, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $44.90
Upside: +2.46%
Praxis Precision Medicines
Nov 6, 2025
Maintains: Underperform
Price Target: $73 → $77
Current: $191.83
Upside: -59.86%
Stoke Therapeutics
Nov 5, 2025
Maintains: Outperform
Price Target: $22 → $32
Current: $30.96
Upside: +3.36%
Astria Therapeutics
Oct 15, 2025
Downgrades: Neutral
Price Target: $28 → $13
Current: $13.10
Upside: -0.76%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.68
Upside: +199.32%
PepGen
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.33
Upside: +50.09%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $12.52
Upside: +43.83%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $5.93
Upside: +136.29%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $44.69
Upside: -3.78%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $35.39
Upside: -9.58%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $3.38
Upside: +48.15%
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.87
Upside: +138.50%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $153.75
Upside: -8.29%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $36.60
Upside: -7.10%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.86
Upside: +129.15%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $126.75
Upside: +2.56%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $181.82
Upside: -33.45%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $13.38
Upside: -70.10%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $42.61
Upside: -38.98%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.64
Upside: +83.49%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $22.05
Upside: +31.55%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.34
Upside: +61.29%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $32.49
Upside: +29.29%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.67
Upside: +1,542.77%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $9.77
Upside: -48.82%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.82
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $5.06
Upside: -1.19%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.61
Upside: +1,445.27%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $10.70
Upside: +6,628.97%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $220.51
Upside: +26.98%